Form 4 for APRE Aprea Therapeutics, Inc.
Accepted 2024-10-16 00:00:00 ET · period of report 2024-10-15 · accession 0001104659-24-108964 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-10-16 | 2024-10-15 | APRE | Gilad Oren | Pres, CEO, Dir | P - Purchase | $2.90 | +250 | 332.9K | +0.1% | +$725 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-10-15 | P | A | 250 | $2.90 | 332,895 | D | — | — |